Integris Medtech Limited
Bookbuilding IPO · NSE, BSE
- Price band
- Unavailable
- Lot size
- Unavailable
- Issue amount
- ₹0 cr
- Total subscription
- Not open
- Opens
- 27 Nov 2026
- Closes
- 1 Dec 2026
- Allotment
- 2 Dec 2026
- Listing
- 4 Dec 2026
Offer at a glance
Issue overview
- Issue size
- —
- Face value
- ₹1 per share
- Minimum application
- Unavailable
- Fresh issue
- ₹600 cr
- Offer for sale
- ₹0 cr
- Registrar
- Kfin Technologies Limited
- Listing exchange
- NSE, BSE
- Issue type
- Bookbuilding IPO
- Shares before issue
- 10,83,38,049
- Shares after issue
- 0
Subscription & GMP
Subscription by category
Bidding has not opened. Subscription figures will appear after bidding starts.
GMP history
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Mar-25 |
|---|---|
| EPS | 6.52 |
| ROE | 5.35 |
| ROCE | 14.51 |
| RONW | 1.48 |
| PRE IPO(PE) | 0 |
| POST IPO(PE) | 0 |
Values and labels as reported in the issue data.
Company information
Company profile
Integris Medtech Limited, incorporated in 2008, is a diversified India-based global medical products and laboratory solutions company. The company develops, manufactures, commercializes, and sells a broad portfolio of medical devices and solutions, including cardiovascular devices, clinical diagnostics, and scientific laboratory solutions. With manufacturing facilities located in India, Germany, and the Netherlands, Integris Medtech supplies products to over 65 international markets, including India, Europe, and Southeast Asia. Its extensive customer base comprises more than 9,500 laboratories and 2,000 hospitals and cathlabs, supported by a diverse portfolio exceeding 22,000 SKUs across more than 200 brands in the laboratory and cardiovascular segments.
Strengths
- Diverse Product Portfolio: Integris Medtech offers a wide range of medical devices and laboratory solutions, including over 22,000 SKUs across cardiovascular and laboratory segments.
- Global Manufacturing Footprint: With manufacturing facilities in India, Germany, and the Netherlands, the company effectively serves over 65 international markets.
- Strong Customer Base: The company supports more than 9,500 laboratories and 2,000 hospitals, demonstrating significant market penetration and customer trust.
- Commitment to Innovation: Integris Medtech has supported over 15,000 patients across 100+ clinical trial sites globally, highlighting its focus on clinical evidence and innovative MedTech solutions.
Risk factors
- Regulatory Challenges: The medical device industry is subject to stringent regulations, which can impact product development timelines and market entry.
- Market Competition: The company faces intense competition from established players in the medical devices and laboratory solutions sectors, which may affect pricing and market share.
- Supply Chain Dependencies: Reliance on global supply chains for manufacturing components may expose the company to disruptions and increased costs.
- Customer Concentration Risk: A significant portion of revenue may come from a limited number of customers, posing risks if any major customer reduces orders.
Promoters
Not Available
Registrar & documents
Lead manager
ICICI Securities Limited, Axial Capital Private Limited, Citigroup Global Markets India Private Limited, IIFL Capital Services Limited
Registrar & contacts
Kfin Technologies Limited
[email protected]Official registrar portal ↗Find your IPO registrar →Registered office
Integris Medtech Ltd., 1 st FloorMetro Tower LSCM.O.R Land, New Rajinder Nagar, 1 st Floor, Metro Tower LSC, M.O.R Land, North Delhi, New Delhi, 110060
+91 120 4531422
[email protected]Company website ↗Frequently Asked Questions
What is Integris Medtech IPO GMP today?
A reliable GMP quote for Integris Medtech is unavailable. Missing quotes and provider placeholders are not reported as zero.
What is the lot size and minimum investment for Integris Medtech IPO?
The minimum application quantity and amount are awaiting verification against the official offer document.
When will Integris Medtech IPO allotment status be announced?
The allotment status for Integris Medtech IPO is scheduled to be finalized on 2 Dec 2026. If you applied for the IPO, you can verify whether shares have been allocated to your Demat account through Kfin Technologies Limited's official portal or via BSE/NSE allotment portals.
How can I check Integris Medtech IPO allotment status online by PAN?
To check Integris Medtech IPO allotment status: 1) Visit the registrar portal (Kfin Technologies Limited) or the BSE IPO allotment page. 2) Select 'Integris Medtech Limited' from the company dropdown. 3) Choose 'PAN' as your identification mode and enter your 10-digit Permanent Account Number. 4) Click 'Search' to view your allotted share quantity and application status.
Related IPO tools
Compare reported premiums or model your investment using this issue’s trading lot and price. Confirm application requirements in the offer document.